Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

Fig. 3

Mean change in total back pain (a), nocturnal back pain (b), and BASFI (c) over time. Patients initially randomized to receive placebo received open-label upadacitinib beginning at week 14. MMRM and AO analyses were used. Δ change, AO as observed, BASFI Bath Ankylosing Spondylitis Functional Index, CI confidence interval, MMRM mixed-effects model repeated measures, QD once daily, SD standard deviation, W week

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us